For several years the IMP/GMP-preferring cytosolic 5'-nucleotidase II (cN-II) has been considered as a therapeutic target in oncology. Indeed, various reports have indicated associations between cN-II expression level and resistance to anticancer agents in several cancer cell lines and in patients affected with neoplasia, mainly by hematologic malignancies. In this paper we present evidence showing that, among the commonly used cytotoxic nucleoside analogs, fludarabine can act as a cN-II inhibitor. In vitro studies using the wild type recombinant cN-II demonstrated that fludarabine inhibited enzymatic activity in a mixed manner (Ki 0.5 mM and Ki' 9 mM), whereas no inhibition was observed with clofarabine and cladribine. Additional experiments with mutant recombinant proteins and an in silico molecular docking indicated that this inhibition is due to an interaction with a regulatory site of cN-II known to interact with adenylic compounds. Moreover, synergy experiments between fludarabine and 6-mercaptopurine in human follicular lymphoma (RL) and human acute promyelocytic leukemia (HL-60) cells transfected with control or cN-II-targeting shRNA-encoding plasmids, showed synergy in control cells and antagonism in cells with decreased cN-II expression. This is in line with the hypothesis that fludarabine acts as a cN-II inhibitor and supports the idea of using cN-II inhibitors in association with other drugs to increase their therapeutic effect and decrease their resistance.
|Autori:||Cividini, Federico; Pesi, Rossana; Chaloin, L; Allegrini, S; Camici, Marcella; Cros Perrial, E; Dumontet, C; Jordheim, Lp; Tozzi, Maria Grazia|
|Titolo:||The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor|
|Anno del prodotto:||2015|
|Digital Object Identifier (DOI):||10.1016/j.bcp.2015.01.010|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|2015 - Cividini et al_ BiochePharm_Fludadarabina_PrePrint.pdf||Documento in Pre-print||Open AccessVisualizza/Apri|